March 2, 2016

Director's Letter

Carole Baggerly

Director, GrassrootsHealth

Vitamin D is great for prevention of disease, but what about treatment after you've been diagnosed? We will study and report on leading-edge treatments using vitamin D as we find them. One treatment protocol that we are excited to share with you is for Multiple Sclerosis (MS). Since March is National Multiple Sclerosis month, now is the perfect time to bring it out into the light.

The protocol we'll be highlighting in this newsletter was developed by Dr. Cicero Coimbra of Brazil. As with all in our panel of scientists, Dr. Coimbra is dedicated to his research and his patients. He has seen thousands of patients at his clinic and has started to replicate his practice in other countries. We are hoping to further define this protocol with him to see what can be implemented as a standard-of-practice world-wide.

One note, this newsletter profiles a specific treatment protocol - not yet a recommendation from GrassrootsHealth. If you have, or know someone with MS, please take the time to read the article and watch the many recommended videos. Then, find a doctor who is well versed in this protocol. Do not try it alone.

How can you act? Throughout this month we will be reporting on the connection of vitamin D and MS. There is a strong correlation. Reach out to those you know, to MS societies, to your local journalist. Let them know that there is a connection and refer them to this (and future) newsletters. We are already working on one of our 'Moving Research into Practice' Protocols for Multiple Sclerosis. We will keep you informed.

Onwards!

**Of note, please take advantage of our March Special to get a vitamin D test kit for less than $50!**

Carole Baggerly

Director, GrassrootsHealth

A Public Health Promotion & Research Organization

Moving Research into Practice NOW!

A New Translational Research Protocol:

Using 1000 IU/day per kg Body Weight to Force MS Into Remission

Cicero G. Coimbra, MD, PhD

Associate Professor

Department of Neurology and Neurosurgery

Federal University of Sao Paulo, UNIFESP

President, Autoimmunity Investigation and Research Institute

About Dr. Cicero Coimbra

Dr. Coimbra received his medical degree from the Universidade Federal do Rio Grande do Sul in 1979. He did two years of internal medical residency and two years of adult neurology residency at the Hospital de Clínicas de Porto Alegre, Brazil; followed by a year of fellowship training in pediatric neurology at Jackson Memorial Hospital, Miami. Coimbra earned his PhD in clinical neurology from the Federal University of São Paulo in 1990. He has also completed post PhD training in experimental brain ischemia at the Laboratory for Brain Research, University of Lund, Sweden. He is currently Associate Professor in the Department of Neurology and Neurosurgery, Federal University of Sao Paulo, UNIFESP.

Click to watch short video

The making of a new protocol

Dr. Coimbra wanted to change lives, to treat neurological disorders. After his fellowship, Coimbra started doing experimental research by inducing ischemic brain damage in rats (in São Paulo, Brazil and Lund, Sweden) and testing different treatments to see what worked. Moderate hypothermia (body temperature reduced to 33 degrees Celsius) provided robust protection to the rat brain. Conversely, postischemic hyperthermia was detrimental, and could trigger a chronic neurodegenerative process. Administration of choline - a natural component of neuronal membranes - provided a moderate protection, suggesting that restricted availability of choline after transient brain ischemia was critical for cell membrane repair and consequent neuronal survival.

"Seeing MS patients getting back to a normal life, young people no longer at risk of going blind or paraplegic - such experience gives great satisfaction to the doctor who has them under his/her care. It has been very gratifying." - Dr. Coimbra

Following a general rule for research work, Coimbra needed to be as up to date as possible on the latest findings related to his field of interest (clinical neuroscience). He realized that much of the therapeutic progresses achieved from clinical and experimental research had not been moved to clinical practice. In spite of their immediate clinical applicability, these practices were not being taught in medical schools - even after several confirmatory reports. At a certain point Coimbra was convinced vitamin D would be a fundamental therapeutic resource, as it stimulates the production of several neuroregenerative substances in the brain.

Coimbra began administering vitamin D in physiological doses (10,000 IU/day) to Parkinson's patients around the year 2001. He noticed that an extensive depigmented area on the forehead of one of his Parkinson's patients (who had also vitiligo - an autoimmune disorder) had virtually disappeared after 3 months on that daily dose. Searching the medical literature for the effects of vitamin D on the immune system revealed a significant number of published papers supporting a fundamental immunoregulatory role of that steroid, that vitamin D is actually a precursor of a powerful hormone that targets receptors in virtually all human cells to control a wide range of biological functions. Since MS is the most common neurological autoimmune disease and a major cause of incapacitating disabilities (like blindness, paraplegia) in young people, he decided to start treating MS patients in 2002 initially using similar doses of vitamin D.

What is a physiological dose of vitamin D?

Coimbra believes that 10,000 IU/day of vitamin D is a physiological dose. This is the amount of vitamin D a young person makes if they are light skinned, wearing shorts and a t-shirt for about 20-30 minutes of mid-day sun. This daily dose is totally safe. No precautions are necessary. It is worth noting that the IOM indicated that 10,000 IU/day was considered the "NOAEL"--the 'no observed adverse effect level'.

Coimbra calls the RDA a "paltry dose, although still officially recommended."

Why does vitamin D work?

The active form of vitamin D is the main regulator of the immune system. It empowers the innate immunity against microorganisms and suppresses autoimmunity (which is dependent on an abnormal "program" of immune activities known as "Th17", and is powerfully counteracted by vitamin D). Vitamin D also induces the proliferation of regulatory immune cells called "regulatory T lymphocytes." There is a vitamin D receptor (VDR) in every cell of the immune system. Vitamin D modifies the function of approximately 10% of human genes.

What does Dr. Coimbra's protocol entail?

Coimbra has been able to successfully suppress disease activity in about 95% of MS cases with variable (individually tailored) high daily doses of vitamin D. The doses are set according to the results of laboratory tests in order to compensate for that individual's degree of genetic vitamin D resistance. This resistance seems to underlie the predisposition to (and maintenance of) autoimmune aggression through the Th17 program of activities. As the protocol aims at regulating the immune system, it has been similarly effective in treating several other autoimmune diseases.
He and his team of 5 doctors have treated more than 4,000 patients at his clinic in San Paulo City using the protocol. He has trained 27 physicians who have launched their own clinics in other cities of Brazil and other countries such as Argentina (2), Peru (1), Portugal (1), Spain (1), Italy (3), Croatia (1) and Canada (1). An ophthalmologist in Naples, FL has been recently trained and is preparing to start a research project using the same protocol to treat autoimmune diseases like uveitis - a major cause of blindness in the general population.

The average initial dose for patients in this treatment protocol is about 1000 IU/day per kg of body weight. In addition to vitamin D, he also prescribes vitamin B2; a diet excluding calcium; and extra fluids (minimum 2.5L/day). After 2-3 months, the daily dose of vitamin D is adjusted in response to changes in laboratory test results. After one year the daily dose is further adjusted to compensate for adaptive changes of vitamin D metabolism (not unusual in patients receiving high doses), until a stable level of laboratory parameters is reached for that individual patient, the point at which vitamin D has reached its maximum immunological effect. This is usually achieved at the third or fourth medical appointment, after 2 years on vitamin D therapy.

The blood work that Coimbra is most interested in is the parathyroid hormone (PTH). PTH production is inhibited by vitamin D and his research has shown that vitamin D immune benefit is maximized when circulating PTH has reached the lower limit of its normal (reference) range. Achieving that level of PTH requires variable daily doses of vitamin D because biological resistance to vitamin D is different for each person. PTH values are also used as a safety gauge, as vitamin D intoxication cannot occur if PTH is not fully suppressed. He carefully monitors blood and urinary calcium, to avoid kidney stones. A calcium restricted diet and minimal daily hydration of 2.5 L are imperative precautions to avoid those potential side-effects. He also administers high doses of vitamin B2 (riboflavin). A significant part of the world population (10-15%) are not able to absorb enough vitamin B2 from normal daily doses to enable the chemical reactions within the body that convert D3 into the working form of vitamin D for immune function - 1,25HydroxyD.

After his patients have been at the correct blood level of PTH for 2-3 months, most if not all of the symptoms are gone, depending on whether permanent disabilities were already established before the beginning of vitamin D therapy. They are considered to be in remission as they no longer have relapses, nor new lesions in their MRI images. They no longer expect to be blind or paraplegic, or to become disabled. They have their life back!

After the third or fourth appointment, Coimbra recommends his patients return in 2 years and again in 5 years for a review appointment and to make sure that no further adjustment of their vitamin D dosage is necessary. Right now most patients are still on very high doses of vitamin D (in some cases levels up to or even higher than 4,000 ng/mL are required to maintain PTH around its lowest normal level and suppressed disease activity due to their very high degree of resistance to both beneficial and toxic effects of vitamin D; in most patients the circulating levels are within the range of 250-1,000 ng/mL). He has not been practicing long enough to determine how long high circulating levels of vitamin D have to be maintained to keep MS in remission.

Do you think it was the chicken or the egg?

Does low vitamin D cause MS? Or does MS cause low vitamin D?

Coimbra feels low vitamin D associated with genetically inherited vitamin D resistance and stressful life events trigger MS and other autoimmune disorders. Vitamin D is a natural, powerful inhibitor of autoimmune reactions. He cites latitude charts of MS incidence (the farther you are from the equator - the more prevalent the disease) as the initial epidemiological data which triggered intensive research and cumulative evidence - enabling development of his protocol.

More Information

Physicians interested in knowing the Coimbra vitamin D3 for MS protocol can write to: coimbraprotocol@leonardorubini.org

Editor's Letter

Susan Siljander

Marketing Director, GrassrootsHealth

To prepare for this month I worked closely with both Dr. Coimbra and a few of his patients. I am part of a new Facebook group and I watched many videos on this protocol. It has been a very exciting time for me, as I found Dr. Coimbra's dedication and passion to be OVER THE TOP! He sees so many patients daily, he oversees other doctors, and yet he still takes the time to answer personal emails from his patients or from people like me wanting to find out more. I was very humbled to work with him. I wish him the best in his practice in Brazil, his research, and the clinics that have started his protocol.

At the same time I really like the changes I have seen in the large MS organizations (e.g. National MS Society, MS Association of America). More about this next week, but I notice there is a lot of mainstream information about vitamin D - I think they are starting to "get it." This makes me hopeful that vitamin D will make a change in the MS community.

So, as Carole says.... Onwards!

Susan Siljander

Marketing Director, GrassrootsHealth

A Public Health Promotion & Research Organization

Moving Research Into Practice NOW!

Order Now

Order Your Home Vitamin D Test TODAY!

Your participation in this project provides information for your answers to D questions and helps fund the GrassrootsHealth projects.

On the Web

Vitamin D Protocol

Web page in English

Written by a patient with a video testimonial

Good summary of the protocol

Go to web page

Only Under Doctor Supervision

This newsletter is in no way intended to encourage or push patients to begin high dose Vitamin D therapy without the opinion and consent of a medical doctor. Health risks can be serious and may involve toxicity, other drug interactions, or organ damage.

Doses over 10,000 IU/day, if not managed properly may cause irreversible damage of renal function or cause other medical complications.

It is important to understand that doses of vitamin D are specifically calculated by Dr. Coimbra based on individual patient parameters during the medical examination. Therefore, it is necessary to seek treatment with high dose vitamin D from an experienced medical doctor.

Research Paper

A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis

Danilo C. Finamor et al.

Federal University, Sao Paulo, Brazil

Published in Dermato-Endocrinology 5:1, 1-13; January/February/March 2013

Read Paper

Watch These Videos

Interview of Dr. Cicero G. Coimbra, MD, PhD

by Leonardo Rubini, a former Italian patient

(Portuguese with English sub-titles)

March 2014

Watch Interview

Dr. Coimbra explains his treatment

Presented to the House Chamber, Brazil Federal Government

(Portuguese with English sub-titles)

August 2013

Watch Video

More than 10 years treatment of MS with vitamin D

Daniel Cunha

Interview with Junia, Marcia and Nayra about the family's experience with the vitamin D treatment. Nayra was diagnosed with MS more than 10 years ago and is probably one of the first patients with MS treated with vitamin D Coimbra

(Portuguese with English subtitles)

December 2012

Watch Video